Compare SINT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | APRE |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.6M |
| IPO Year | 2007 | 2019 |
| Metric | SINT | APRE |
|---|---|---|
| Price | $2.40 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.00 | $4.10 |
| AVG Volume (30 Days) | 42.6K | ★ 292.6K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.45 | 21.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,018,000.00 | N/A |
| Revenue This Year | $30.26 | N/A |
| Revenue Next Year | $413.20 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.55 |
| 52 Week High | $6.78 | $2.22 |
| Indicator | SINT | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 55.74 |
| Support Level | $2.30 | $0.75 |
| Resistance Level | $2.97 | $0.98 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 47.67 | 43.37 |
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.